Fluoxetine treatment of children and adolescents with tourette’s and obsessive compulsive disorders

Preliminary clinical experience

Mark A Riddle, Maureen T. Hardin, Robert King, Larry Scahill, Joseph L. Woolston

Research output: Contribution to journalArticle

Abstract

Fluoxetine hydrochloride is the first selective serotonin uptake inhibitor introduced commercially in the United States. This report describes preliminary clinical experience with fluoxetine in 10 children and adolescents, aged 8 to 15 years, with primary obsessive compulsive disorder (OCD) or Tourette’s syndrome (TS) plus OCD. In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated. Adverse effects included behavioral agitation/activation in four patients and mild gastrointestinal symptoms in two patients. No abnormalities were noted in the seven children who had follow-up EKGs. Five of the 10 patients (50%) were considered responders; their obsessive-compulsive symptoms decreased substantially during treatment with fluoxetine. Responder rates were similar in the primary OCD (two of four, 50%) and TS + OCD (three of six, 50%) groups. In conclusion, short-term fluoxetine administration appears to be safe in children and adolescents. Placebo-controlled trials are needed to further assess the efficacy of fluoxetine.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume29
Issue number1
StatePublished - 1990
Externally publishedYes

Fingerprint

Fluoxetine
Obsessive-Compulsive Disorder
Tourette Syndrome
Therapeutics
Serotonin Uptake Inhibitors
Electrocardiography
Placebos

Keywords

  • Fluoxetine
  • Obsessive compulsive disorder
  • Psychopharmacology
  • Tourette’s syndrome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Fluoxetine treatment of children and adolescents with tourette’s and obsessive compulsive disorders : Preliminary clinical experience. / Riddle, Mark A; Hardin, Maureen T.; King, Robert; Scahill, Larry; Woolston, Joseph L.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 29, No. 1, 1990, p. 45-48.

Research output: Contribution to journalArticle

@article{5b6692bbbf94432296fa4e8de9e1a028,
title = "Fluoxetine treatment of children and adolescents with tourette’s and obsessive compulsive disorders: Preliminary clinical experience",
abstract = "Fluoxetine hydrochloride is the first selective serotonin uptake inhibitor introduced commercially in the United States. This report describes preliminary clinical experience with fluoxetine in 10 children and adolescents, aged 8 to 15 years, with primary obsessive compulsive disorder (OCD) or Tourette’s syndrome (TS) plus OCD. In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated. Adverse effects included behavioral agitation/activation in four patients and mild gastrointestinal symptoms in two patients. No abnormalities were noted in the seven children who had follow-up EKGs. Five of the 10 patients (50{\%}) were considered responders; their obsessive-compulsive symptoms decreased substantially during treatment with fluoxetine. Responder rates were similar in the primary OCD (two of four, 50{\%}) and TS + OCD (three of six, 50{\%}) groups. In conclusion, short-term fluoxetine administration appears to be safe in children and adolescents. Placebo-controlled trials are needed to further assess the efficacy of fluoxetine.",
keywords = "Fluoxetine, Obsessive compulsive disorder, Psychopharmacology, Tourette’s syndrome",
author = "Riddle, {Mark A} and Hardin, {Maureen T.} and Robert King and Larry Scahill and Woolston, {Joseph L.}",
year = "1990",
language = "English (US)",
volume = "29",
pages = "45--48",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Fluoxetine treatment of children and adolescents with tourette’s and obsessive compulsive disorders

T2 - Preliminary clinical experience

AU - Riddle, Mark A

AU - Hardin, Maureen T.

AU - King, Robert

AU - Scahill, Larry

AU - Woolston, Joseph L.

PY - 1990

Y1 - 1990

N2 - Fluoxetine hydrochloride is the first selective serotonin uptake inhibitor introduced commercially in the United States. This report describes preliminary clinical experience with fluoxetine in 10 children and adolescents, aged 8 to 15 years, with primary obsessive compulsive disorder (OCD) or Tourette’s syndrome (TS) plus OCD. In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated. Adverse effects included behavioral agitation/activation in four patients and mild gastrointestinal symptoms in two patients. No abnormalities were noted in the seven children who had follow-up EKGs. Five of the 10 patients (50%) were considered responders; their obsessive-compulsive symptoms decreased substantially during treatment with fluoxetine. Responder rates were similar in the primary OCD (two of four, 50%) and TS + OCD (three of six, 50%) groups. In conclusion, short-term fluoxetine administration appears to be safe in children and adolescents. Placebo-controlled trials are needed to further assess the efficacy of fluoxetine.

AB - Fluoxetine hydrochloride is the first selective serotonin uptake inhibitor introduced commercially in the United States. This report describes preliminary clinical experience with fluoxetine in 10 children and adolescents, aged 8 to 15 years, with primary obsessive compulsive disorder (OCD) or Tourette’s syndrome (TS) plus OCD. In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated. Adverse effects included behavioral agitation/activation in four patients and mild gastrointestinal symptoms in two patients. No abnormalities were noted in the seven children who had follow-up EKGs. Five of the 10 patients (50%) were considered responders; their obsessive-compulsive symptoms decreased substantially during treatment with fluoxetine. Responder rates were similar in the primary OCD (two of four, 50%) and TS + OCD (three of six, 50%) groups. In conclusion, short-term fluoxetine administration appears to be safe in children and adolescents. Placebo-controlled trials are needed to further assess the efficacy of fluoxetine.

KW - Fluoxetine

KW - Obsessive compulsive disorder

KW - Psychopharmacology

KW - Tourette’s syndrome

UR - http://www.scopus.com/inward/record.url?scp=0025008647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025008647&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 45

EP - 48

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 1

ER -